Susquehanna International Group
VVOS icon

Susquehanna International Group’s Vivos Therapeutics VVOS Stock Holding History

Susquehanna International Group’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,648
Closed -$110K – 14052
2022
Q1 		$110K Sell
1,648
-1,080
-40% -$70.6K ﹤0.01% 11840
2021
Q4 		$153K Sell
2,728
-832
-23% -$67K ﹤0.01% 11767
2021
Q3 		$360K Buy
+3,560
New +$374K ﹤0.01% 10182

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AF
Apexium Financial Dallas, Texas $2.06B AUM 15.96% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Susquehanna International Group's VVOS Position: Q4 2022 in Review

Susquehanna International Group sold out of Vivos Therapeutics (VVOS) in Q4 2022, closing a stake of 1,659 shares — an estimated $27K sold.

Susquehanna International Group first reported a position in VVOS in Q3 2021 and held it in 4 quarters. The position peaked at $222K in Q3 2021. 27 funds tracked by Wall St. Rank hold VVOS as of Q4 2022.

  • Susquehanna International Group reported no remaining Vivos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Susquehanna International Group sold 1,659 Vivos Therapeutics shares in Q4 2022, an estimated $27K.
  • Susquehanna International Group first reported a position in Vivos Therapeutics in Q3 2021 and held it in 4 quarters.
  • Susquehanna International Group's Vivos Therapeutics position peaked at $222K in Q3 2021.
  • 27 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q4 2022.

Based on Susquehanna International Group's 13F filing for Q4 2022, filed 14 Feb 2023.